Keyphrases
Janus Kinase 2 (JAK2)
100%
Janus Kinase Inhibitors
51%
JAK Inhibitors
40%
SND1
32%
Isoform Selectivity
32%
Pseudokinase Domain
31%
Myeloproliferative Neoplasms
31%
RNA-binding Protein
26%
RNA Binding
24%
Navitoclax
24%
MiR-1-3p
24%
High-throughput Screening
24%
Cancer Cells
24%
Hypoxia
24%
In Vitro Profiling
24%
Leukemia
24%
Inhibitor Screening
24%
Activity Assay
24%
Rheumatic Diseases
24%
Hypoxia-related Genes
24%
Erythropoietin Receptor
24%
Small Molecule Ligands
24%
Gene Expression
24%
Tudor-SN
24%
Janus Kinase
24%
Drug Selectivity
24%
Functional Characterization
24%
Structural Characterization
24%
Kinase Regulation
24%
JAK2V617F
23%
Family Members
20%
MicroRNA
18%
Knock-in Mouse Model
16%
Granule Proteins
16%
Liver
16%
MiR-96
16%
Chemical Space
16%
Kinase Activity
15%
Small Molecules
14%
Binder
14%
Erythropoietin
14%
Deregulation
13%
Cytokine Inhibitors
12%
Binding Mode
11%
X-ray Crystal Structure
11%
Janus Kinase 1 (JAK1)
10%
Tyrosine Kinase 2 (TYK2)
8%
Evolutionarily Conserved
8%
On Demand
8%
Gene number
8%
Biochemistry, Genetics and Molecular Biology
Janus Kinase 2
72%
Cytokine
49%
Phosphotransferase
41%
Kinase
41%
Janus Kinase Inhibitor
40%
SND1
32%
Isoform
28%
RNA-binding Protein
26%
Janus Kinase
24%
RNA Binding
24%
High Throughput Screening
24%
Cancer Cell
24%
MicroRNA
24%
Transcription
24%
Erythropoietin Receptor
24%
Gene Expression
24%
Drug Selectivity
24%
Artificial Intelligence
24%
Enzyme
24%
Small Molecule
18%
Knockout Mouse
16%
Messenger RNA
16%
Adenosine Triphosphate
16%
Erythropoietin
8%
Upregulation
8%
Gene Deletion
8%
RNA Splicing
8%
Stress Granule
8%
Myeloid
8%
Body Size
8%
Organ Size
8%
Biotin
8%
Tyrosine Kinase
8%
Janus Kinase 1
8%
Mediator
8%
Receptor Tyrosine Kinase
8%
Suramin
7%
Crystal Structure
6%
X Ray
6%
Dimerization
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cytokine
59%
Janus Kinase Inhibitor
51%
Janus Kinase 2 Inhibitor
48%
Phosphotransferase
36%
Janus Kinase 1
32%
Janus Kinase
27%
Myeloproliferative Neoplasm
25%
High-Throughput Screening
24%
Navitoclax
24%
microRNA 1
24%
Leukemia
24%
Malignant Neoplasm
24%
Janus Kinase 2
24%
Rheumatic Disease
24%
Drug Selectivity
24%
Adenosine Triphosphate
21%
microRNA
14%
Suramin
14%
Autoimmune Disease
13%
Erythropoietin
12%
Tumor Suppressor Protein
9%
Hematologic Disease
8%
Pacritinib
8%
Fedratinib
8%
Momelotinib
8%
Binding Site
8%
Ruxolitinib
8%
Side Effect
8%
Protein Tyrosine Kinase
8%
Inflammatory Disease
8%
Drug Discovery
6%
